We found in the press release that was published by Inovio Pharmaceuticals (INO) last week that the company's COVID-19 vaccine, INO-4800, which seems to be more anti-viral and more safe properties, this probably is main factor that it needs more time.
Results in new study showed INO-4800 induced a robust T cell response against all spike protein variants tested, and the company believes that it will be key in providing protection against SARS-CoV-2 variants, in addition to providing similar levels of neutralizing activity against both the UK and Brazilian variants as those against the original strain.
In total, the study showed how the combination of robust T cell responses in conjunction with neutralizing antibody responses provide an important defense against both emerging and potential future viral variants, exhibiting broad protection against the virus and less impacted by the mutational changes a virus may undergo.
The company said that it will report Phase 2 results in 2Q, and with FDA concurrence, expects to move into Phase 3 in the second quarter of this year. The company also said that its COVID vaccine's projected safety profile, its stability at room temperature for more than a year, and likely ability to safely boost numerous times positions INOVIO's COVID-19 vaccine.
But anyway, people are waiting for its vaccine that will be in the market as soon as possible, and investors as well. The company's stock fell slightly over the past month.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.